MIDLOTHIAN, Va., Sept. 29, 2021 /PRNewswire/ -- Pulmotect reported positive topline results from their randomized, placebo-controlled Phase-2 trial of PUL-042 against COVID-19. Patients treated with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results